These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 22086553)

  • 1. P2X receptor antagonists for pain management: examination of binding and physicochemical properties.
    Gum RJ; Wakefield B; Jarvis MF
    Purinergic Signal; 2012 Feb; 8(Suppl 1):41-56. PubMed ID: 22086553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neural-glial purinergic receptor ensemble in chronic pain states.
    Jarvis MF
    Trends Neurosci; 2010 Jan; 33(1):48-57. PubMed ID: 19914722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The regulation of osteoblast function and bone mineralisation by extracellular nucleotides: The role of p2x receptors.
    Orriss IR; Key ML; Brandao-Burch A; Patel JJ; Burnstock G; Arnett TR
    Bone; 2012 Sep; 51(3):389-400. PubMed ID: 22749889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Painful purinergic receptors.
    Donnelly-Roberts D; McGaraughty S; Shieh CC; Honore P; Jarvis MF
    J Pharmacol Exp Ther; 2008 Feb; 324(2):409-15. PubMed ID: 18042830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory role of supraspinal P2X3/P2X2/3 subtypes on nociception in rats.
    Fukui M; Nakagawa T; Minami M; Satoh M; Kaneko S
    Mol Pain; 2006 Jun; 2():19. PubMed ID: 16753051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states.
    Donnelly-Roberts DL; Jarvis MF
    Br J Pharmacol; 2007 Jul; 151(5):571-9. PubMed ID: 17471177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2/3 receptors with in vivo efficacy in a pain model.
    Ballini E; Virginio C; Medhurst SJ; Summerfield SG; Aldegheri L; Buson A; Carignani C; Chen YH; Giacometti A; Lago I; Powell AJ; Jarolimek W
    Br J Pharmacol; 2011 Jul; 163(6):1315-25. PubMed ID: 21410458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Molecular Determinants of Small-Molecule Ligand Binding at P2X Receptors.
    Pasqualetto G; Brancale A; Young MT
    Front Pharmacol; 2018; 9():58. PubMed ID: 29456508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purinergic P2 receptors as targets for novel analgesics.
    Burnstock G
    Pharmacol Ther; 2006 Jun; 110(3):433-54. PubMed ID: 16226312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nociceptive signaling mediated by P2X3, P2X4 and P2X7 receptors.
    Inoue K; Tsuda M
    Biochem Pharmacol; 2021 May; 187():114309. PubMed ID: 33130129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular physiology of P2X receptors.
    North RA
    Physiol Rev; 2002 Oct; 82(4):1013-67. PubMed ID: 12270951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of aurintricarboxylic acid as a potent allosteric antagonist of P2X1 and P2X3 receptors.
    Obrecht AS; Urban N; Schaefer M; Röse A; Kless A; Meents JE; Lampert A; Abdelrahman A; Müller CE; Schmalzing G; Hausmann R
    Neuropharmacology; 2019 Nov; 158():107749. PubMed ID: 31461640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P2X receptors: New players in cancer pain.
    Franceschini A; Adinolfi E
    World J Biol Chem; 2014 Nov; 5(4):429-36. PubMed ID: 25426266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contributions of P2X3 homomeric and heteromeric channels to acute and chronic pain.
    Jarvis MF
    Expert Opin Ther Targets; 2003 Aug; 7(4):513-22. PubMed ID: 12885270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P2X purinergic receptor knockout mice reveal endogenous ATP modulation of both vasopressin and oxytocin release from the intact neurohypophysis.
    Custer EE; Knott TK; Cuadra AE; Ortiz-Miranda S; Lemos JR
    J Neuroendocrinol; 2012 Apr; 24(4):674-80. PubMed ID: 22340257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist.
    Gever JR; Soto R; Henningsen RA; Martin RS; Hackos DH; Panicker S; Rubas W; Oglesby IB; Dillon MP; Milla ME; Burnstock G; Ford AP
    Br J Pharmacol; 2010 Jul; 160(6):1387-98. PubMed ID: 20590629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nociceptive transmission and modulation via P2X receptors in central pain syndrome.
    Kuan YH; Shyu BC
    Mol Brain; 2016 May; 9(1):58. PubMed ID: 27230068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for the involvement of spinal endogenous ATP and P2X receptors in nociceptive responses caused by formalin and capsaicin in mice.
    Tsuda M; Ueno S; Inoue K
    Br J Pharmacol; 1999 Dec; 128(7):1497-504. PubMed ID: 10602329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of cloned P2X receptors.
    North RA; Surprenant A
    Annu Rev Pharmacol Toxicol; 2000; 40():563-80. PubMed ID: 10836147
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.